Merck KGaA (MKGAF)
(Delayed Data from OTC)
$157.08 USD
-8.25 (-4.99%)
Updated Apr 26, 2024 01:14 PM ET
4-Sell of 5 4
A Value F Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MKGAF 157.08 -8.25(-4.99%)
Will MKGAF be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MKGAF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MKGAF
HEXO (HEXO) Reports Q3 Loss, Lags Revenue Estimates
Catalent (CTLT) Reports Q3 Loss, Tops Revenue Estimates
MKGAF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Journey Medical Corporation (DERM) Reports Q1 Loss, Lags Revenue Estimates
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates
Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Misses Revenue Estimates
Other News for MKGAF
908 Devices: Rare Early-Stage Bioprocess Investment Opportunity
Week In Review: 3 Multinationals Plan Investments In Southeast Asia Facilities
Merck KGaA: Moving To A Hold As 2025 Targets Are Now Doubtful
Merck KGaA (MKGAF) Q4 2023 Earnings Call Transcript
Merck KGaA Non-GAAP EPS of €8.49, revenue of €20.99B; initiates FY24 outlook